| Crizotinib Arm | Chemotherapy Arm | Incremental |
---|---|---|---|
COSTS | $288,945 | $78,071 | $210,874 |
 Testing | $7215 | $0 | $7215 |
 PFS - First line | $246,127 | $31,218 | $214,909 |
 Progressed - Second line | $11,879 | $22,894 | -$11,015 |
 Progressed - Third line | $12,345 | $13,959 | -$1614 |
 Palliation | $11,379 | $10,001 | $1379 |
LIFE YEARS (LYs) | 3.349 | 2.465 | 0.885 |
 PFS - First line | 2.256 | 1.735 | 0.521 |
 Progressed - Second line | 0.680 | 0.288 | 0.392 |
 Progressed - Third line | 0.155 | 0.175 | −0.020 |
 Palliation | 0.258 | 0.267 | −0.009 |
QALYS | 2.541 | 1.769 | 0.772 |
 PFS - First line | 1.819 | 1.337 | 0.482 |
 Progressed - Second line | 0.449 | 0.190 | 0.259 |
 Progressed - Third line | 0.102 | 0.115 | −0.013 |
 Palliation | 0.170 | 0.126 | 0.044 |
ICER (Cost per LY gained) | Â | $238,394 | |
ICER (Cost per QALY gained) | Â | $273,286 |